Hormone therapy for advanced or recurrent endometrial cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Kokka, Fani ^a   Brockbank, Elly ^a   Oram, David ^a   Gallagher, Chris ^a   Bryant, Andrew ^b   Dickinson, Heather O ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYL 6 DEHYDROPROGESTERONE ACETATE; 6, 17ALPHA DIMETHYL 6 DEHYDROPROGESTERONE; ANASTROZOLE; ARZOXIFENE; CISPLATIN; DANAZOL; DOXORUBICIN; GONADORELIN; HORMONE; HYDROXYPROGESTERONE CAPROATE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PACLITAXEL; PROGESTERONE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENDOMETRIUM CANCER; HORMONAL THERAPY; HOT FLUSH; HUMAN; LEUKOPENIA; LIVER DISEASE; MUCOSA ILAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PROCTITIS; RECURRENT CANCER; REVIEW; STOMATITIS; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VOMITING;

EID: 70049094220     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007926     Document Type: Review

References (51)

1. Aalders JG, Abeler V, Kolstad P. Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma: a clinical and histopathological study of 175 patients. Gynecologic Oncology 1984;17(1):64-74. (Pubitemid 14176293)
2. Ackerman I. Malone S. Thomas G. Franssen E. Balogh J. Dembo A. Endometrial carcinoma - relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecologic Oncology 1996;60(2):177-183 (Pubitemid 26058760)
3. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. International Journal of Cancer 1975;15(4):617-631
4. Asbury RF, Brunetto VL, Lee RB, Reid G, Rocereto TF. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. American Journal of Clinical Oncology 2002;25(6):557-560 (Pubitemid 35453658)
5. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. International Journal of Gynaecology and Obstetrics 2000;70(2):209-262
6. Berek JS, Hacker NF. Practical Gynecologic Oncology. 4th Edition. Lippincott, Williams and Wilkins, 2005.
7. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The Results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;Vol.50(No.6):683-691 (Pubitemid 27341818)
8. Burke TW, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecologic Oncology 2003;90(2.2):S40-6.
9. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecologic Oncology 2006;101(1):158-167 (Pubitemid 43303577)
10. Chang S, Masse LC, Moser RP, Dodd KW, Arganaraz F, Fuemmler BF. State ranks of incident cancer burden due to overweight and obesity in the United States. Obesity 2008;16(7):1636-1650 (Pubitemid 351915101)
11. Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecologic Oncology 1997;64(1):126-129 (Pubitemid 27026969)
12. Covens A, Brunetto VL, Markman M, Orr JW, Lentz SS, Benda J. Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 2003;89(3):470-474 (Pubitemid 36687794)
13. CTCAE. Common Terminology Criteria for Adverse Events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf ) 9th August 2006; Vol. v3.0 (CTCAE).
14. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. International Journal of Gynecologic Cancer 2007;17(5):964-978 (Pubitemid 47414814)
15. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-188
17. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2004;92(1):10-14 (Pubitemid 38147365)
18. Gallagher CJ, Oliver RT, Oram DH, Fowler CG, Blake PR, Mantell BS. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. British Journal of Obstetrics and Gynaecology 1991;98(10):1037-1041
19. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. . Lyon: IARCPress, 2004.
20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
21. Higgins JPT, Green S (editors). Cochrane Handbook for systematic Reviews of Interventions Version 5.0.0 [updated February] 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org.
22. Hill HA, Austin H. Nutrition and endometrial cancer. Cancer Causes and Control 1996;7(1):19-32.
23. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA: A Cancer Journal for Clinicians 2008;58:71-96.
24. Jeyarajah AR, Gallagher CJ, Blake PR, Oram DH, Dowsett M, Fisher C. Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecologic Oncology 1996;63(1):47-52. (Pubitemid 26337964)
25. Jick H, Watkins RN, Hunter JR, Dinan BJ, Madsen S, Rothman KJ. Replacement estrogens and endometrial cancer. The New England Journal of Medicine 1979;300(5):218-222
26. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiology, Biomarkers and Prevention 2002;11(12):1531-1543 (Pubitemid 36020003)
27. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta Obstetricia et Gynecologica Scandinavica 1984;63(5):441-450 (Pubitemid 14040437)
28. Kitchener HC. Survival from endometrial cancer in England and Wales up to 2001. British Journal of Cancer 2008;99(Supplement 1):S68-9.
29. Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of ClinicalOncology 1996;14(2):357-361 (Pubitemid 26050995)
30. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Research 1998;58(15):3254-3258
31. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. British Journal of Cancer 2008;98(9):1582-1585 (Pubitemid 351652323)
32. Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. International Journal of Gynecologic Cancer 2004;14(4):650-658 (Pubitemid 39062922)
33. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Leuprolide in the treatment of endometrial cancer. Gynecologic Oncology 1997;66(3):542.
34. Markman M. Hormonal therapy of endometrial cancer. European Journal of Cancer 2005;41(5):673-675
35. McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecologic Oncology 2003;90(1):64-69 (Pubitemid 37338077)
36. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. Journal of Clinical Oncology 1991;9(6):1071-1088
37. Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clinical Advances in Hematology and Oncology 2006;4(6):459-468
38. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-2834 (Pubitemid 28562978)
39. Piver MS, Lele S, Barlow JJ. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report. Obstetrics and Gynecology 1980;56(3):370-372 (Pubitemid 10056377)
40. Podratz KC, O'Brien PC, Malkasian GD, Jr, Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in treatment of endometrial carcinoma. Obstetrics and Gynecology 1985;66(1):106-110 (Pubitemid 15047395)
41. Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecologic Oncology 1989;32(1):1-3. (Pubitemid 19029857)
42. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2000;78(2):212-216 (Pubitemid 30650356)
43. Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Review of Anticancer Therapy 2004;4(4):679-689 (Pubitemid 39161999)
44. Sears JD, Greven KM, Hoen HM, Randall ME. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 1994;74(4):1303-1308 (Pubitemid 24301784)
45. Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Critical Reviews in Oncology/Hematology 2008;67(3):204-212
46. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome inmetastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecologic Oncology 2007;106(2):325-333 (Pubitemid 47087930)
47. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clinical Radiology 2007;62:28-34. (Pubitemid 44824747)
48. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control 2009;16(1):38-45.
49. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. Journal of Clinical Oncology 1999;17(6):1736-1744 (Pubitemid 29269242)
50. Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2001;19(2):364-367 (Pubitemid 32112847)
51. Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2004;92(1):4-9. (Pubitemid 38147364)